GlassScriptPhysician profile
Srikanth Kunaparaju
NPI 1467645333
$2,970.30
in general payments reported to CMS, 2019-2025
23 companies · $640 in 2025
The $640 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $434 · 2020: $129 · 2021: $35.99 · 2022: $144 · 2023: $864 · 2024: $723 · 2025: $640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,960 · Education: $268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,959.78 |
| Education | $267.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $523.33 | 2019-2024 | Jynarque |
| Travere Therapeutics, INC. | $358.18 | 2023-2025 | Filspari, Thiola |
| Mallinckrodt Hospital Products INC. | $236.65 | 2023 | Acthar, Terlivaz |
| Vifor Pharma, INC. | $219.62 | 2022-2025 | Veltassa |
| Bayer Healthcare Pharmaceuticals INC. | $156.38 | 2022-2025 | |
| Aurinia Pharma U.S., INC. | $125.88 | 2022-2025 | Lupkynis |
| Akebia Therapeutics INC | $122.00 | 2023-2025 | Vafseo, Auryxia |
| Fresenius USA Marketing, INC. | $118.91 | 2024-2025 | Velphoro, Velphoro |
| Horizon Therapeutics Plc | $116.06 | 2020-2023 | Krystexxa |
| Calliditas Therapeutics US INC. | $112.96 | 2022-2025 | Tarpeyo |
| Ardelyx, INC. | $107.02 | 2023-2025 | Ibsrela |
| Glaxosmithkline, LLC. | $100.39 | 2020-2023 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $100.18 | 2021-2025 | Farxiga, Lokelma |
| Amgen INC. | $92.13 | 2021-2025 | Tavneos |
| Baxter Healthcare | $83.33 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $79.41 | 2023-2025 | |
| Ani Pharmaceuticals, INC. | $74.31 | 2023-2024 | Purified Cortrophin Gel |
| Scpharmaceuticals INC. | $68.35 | 2024-2025 | |
| Lilly USA, LLC | $45.51 | 2023-2025 | Jardiance |
| Kyowa Kirin, INC. | $45.30 | 2023-2024 | Crysvita |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.76 | 2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $25.06 | 2023 | Xarelto |
| Daiichi Sankyo INC. | $24.58 | 2024 | Injectafer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Srikanth Kunaparaju listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.